Ohio State University recorded nearly $1.6 billion in research funding for fiscal year 2024 — a university record — according to the National Science Foundation's annual higher education research and development data. The figure represents a nine percent increase over the prior year and places the university 12th nationally in total research funding and sixth in industry-funded research.

The NSF's Higher Education Research and Development survey remains the benchmark dataset for comparing institutional research portfolios, and the FY2024 numbers mark a measurable milestone for Ohio State's research enterprise. A nine percent year-over-year gain outpaces typical institutional growth rates in academic R&D, though the underlying drivers — federal awards versus corporate partnerships versus philanthropy — are not fully broken out in the announcement.

John Horack, Ohio State's vice president for research, framed the result in terms of personnel rather than infrastructure or funding strategy. "I'm incredibly proud of our researchers, whose creativity and commitment continue to elevate this university's reputation as a powerhouse for innovation and impact," Horack said in a university press release.

The sixth-place ranking in industry research is the more distinctive number. Ohio State attributes that position to long-running corporate partnerships, naming Honda and the biotechnology company Amgen as examples. The scale of these relationships varies considerably.

The Honda partnership is the university's most established industry relationship, spanning 25 years and generating $130 million in philanthropy research, according to the press release. That figure covers a quarter-century of collaboration, not annual spend — a distinction worth noting when assessing the partnership's current budget weight. The relationship also funds research projects, internships and other opportunities for students.

Bob Nelson, American Honda's executive vice president, emphasized the operational nature of the collaboration. "This unique relationship enables us not only to conduct groundbreaking research every day, but to use our combined expertise to explore new and innovative opportunities," Nelson said in the release. "This collaboration provides benefits both to Honda and Ohio State every single day, and that is a testament to the value of this partnership."

The Amgen relationship is newer in character and oriented toward workforce development as much as research output. Amgen develops medicines for cancer, heart disease, osteoporosis and rare diseases. Sandra Rodriguez-Toledo, the company's vice president of site operations, described a direct talent pipeline. "By working directly with Ohio State students, we are helping develop the next generation of talent while demonstrating how applied learning can translate directly from the classroom to impactful outcomes in industry," Rodriguez-Toledo said.

For R&D managers watching university-industry partnering models, the Ohio State case illustrates two distinct structures: a decades-long anchored relationship with an automaker that compounds philanthropic and research investment over time, and a biotech partnership that couples research activity with student training and recruitment. President Walter "Ted" Carter Jr. cast the enterprise broadly in the press release, tying it to "groundbreaking medical treatments, improved technology for Ohio farmers and manufacturers, safer communities and more effective schools."

The rankings and the $1.6 billion figure come from NSF's published data; the characterizations of impact and the partnership claims come from the university's own announcement, which has a clear promotional interest in the framing.

The NSF published its FY2024 higher education research and development data in February 2026, and institutions across the sector will be benchmarking their own industry-funded portfolios against it in the months ahead.